Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Classification of Endometrial Carcinoma

  • Chapter
  • First Online:
Precision Molecular Pathology of Uterine Cancer

Part of the book series: Molecular Pathology Library ((MPLB,volume 11))

Abstract

Like other neoplasms, endometrial carcinoma is usually classified based on the histopathologic type. This approach is supported by the WHO in order to obtain a uniform classification that can be globally used and serve as a common language for patient care, scientific studies, and research. The current histopathologic classification of endometrial carcinoma distinguishes between various types with distinct microscopic features that often are associated with distinct molecular findings and biologic behavior. The WHO classification is updated about every 10 years and reflects state of the art knowledge. In addition to categorization based on histology, an alternative approach to classification has been made that integrates molecular findings and classic pathology. This simplified approach considers the molecular and biologic differences between major subtypes of endometrial carcinoma and tries to propose a pathogenetic model. It will be further developed by novel molecular findings and future developments in understanding endometrial tumorigenesis. A molecular based rather than a purely histomorphologic classification seems to represent a timely approach to classification.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kurman RJ, Carcangiu ML, Herrington S, Young RH (eds) (2014) Tumours of the female reproductive organs. WHO classification of tumours. IARC Press, Lyon.

    Google Scholar 

  2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    Article  CAS  PubMed  Google Scholar 

  3. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  4. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295–308. doi:10.1038/modpathol.3880051.

    Article  CAS  PubMed  Google Scholar 

  5. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol. 1997;10(10):963–8.

    CAS  PubMed  Google Scholar 

  6. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14(8):2263–9. doi:10.1158/1078-0432.CCR-07-4837.

    Article  CAS  PubMed  Google Scholar 

  7. Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol. 2004;12(4):319–31.

    Article  CAS  PubMed  Google Scholar 

  8. Zheng W, Liang SX, Yi X, Ulukus EC, Davis JR, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26(1):38–52. doi:10.1097/01.pgp.0000228138.56222.4e.

    Article  CAS  PubMed  Google Scholar 

  9. Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 2004;12(3):207–23.

    Article  PubMed  Google Scholar 

  10. Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32(4):403–13. doi:10.1038/onc.2012.76.

    Article  CAS  PubMed  Google Scholar 

  11. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62(1):111–23. doi:10.1111/his.12053.

    Article  PubMed  Google Scholar 

  12. Djordjevic B, Barkoh BA, Luthra R, Broaddus RR. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013;26(10):1401–12. doi:10.1038/modpathol.2013.67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814–24.

    Article  CAS  PubMed  Google Scholar 

  14. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57(18):3935–40.

    CAS  PubMed  Google Scholar 

  15. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih Ie M. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625–32. doi:10.1097/PAS.0b013e318212782a.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih Ie M. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104(19):1503–13. doi:10.1093/jnci/djs345.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Catasus L, Matias-Guiu X, Machin P, Munoz J, Prat J. BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest. 1998;78(11):1439–44.

    CAS  PubMed  Google Scholar 

  18. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65(23):10669–73. doi:10.1158/0008-5472.CAN-05-2620.

    Article  CAS  PubMed  Google Scholar 

  19. Bashir S, Jiang G, Joshi A, Miller C Jr, Matrai C, Yemelyanova A, Caputo TA, Holcomb KM, Ellenson LH, Gupta D. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. Int J Gynecol Cancer. 2014;24(7):1262–7. doi:10.1097/IGC.0000000000000183.

    Article  PubMed  Google Scholar 

  20. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17(6):1331–40. doi:10.1158/1078-0432.CCR-10-0540.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.

    Article  CAS  PubMed  Google Scholar 

  22. Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Kobel M, Lee CH, Soslow RA. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28(4):505–14. doi:10.1038/modpathol.2014.143.

    Article  CAS  PubMed  Google Scholar 

  23. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi:10.1038/bjc.2015.190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224(3):328–33. doi:10.1002/path.2911.

    Article  CAS  PubMed  Google Scholar 

  25. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 2004;17(5):530–7. doi:10.1038/modpathol.3800057.

    Article  CAS  PubMed  Google Scholar 

  26. Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Kobel M, Lee CH. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology. 2015;66(5):664–74. doi:10.1111/his.12581.

    Article  PubMed  Google Scholar 

  27. Guan B, Wang TL, Shih le M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27. doi:10.1158/0008-5472.CAN-11-1562.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16(6):600–10.

    Article  CAS  PubMed  Google Scholar 

  29. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150(1):177–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Kuhn E, Bahadirli-Talbott A, Shih Ie M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol. 2014;27(7):1014–9. doi:10.1038/modpathol.2013.209.

    Article  CAS  PubMed  Google Scholar 

  31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.

    Article  CAS  PubMed  Google Scholar 

  32. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 1991;67(12):3093–103.

    Article  CAS  PubMed  Google Scholar 

  33. Zaino RJ, Kurman R, Herbold D, Gliedman J, Bundy BN, Voet R, Advani H. The significance of squamous differentiation in endometrial carcinoma. Data from a Gynecologic Oncology Group study. Cancer. 1991;68(10):2293–302.

    Article  CAS  PubMed  Google Scholar 

  34. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma with squamous cell differentiation. Cancer. 1992;69(2):488–95.

    Article  CAS  PubMed  Google Scholar 

  35. Zaino RJ, Kurman RJ. Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol. 1988;5(2):154–71.

    CAS  PubMed  Google Scholar 

  36. Kim KR, Scully RE. Peritoneal keratin granulomas with carcinomas of endometrium and ovary and atypical polypoid adenomyoma of endometrium. A clinicopathological analysis of 22 cases. Am J Surg Pathol. 1990;14(10):925–32.

    Article  CAS  PubMed  Google Scholar 

  37. Zaino RJ, Kurman RJ, Brunetto VL, Morrow CP, Bentley RC, Cappellari JO, Bitterman P. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol. 1998;22(11):1379–85.

    Article  CAS  PubMed  Google Scholar 

  38. Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol. 2016;29(Suppl 1):S29–44. doi:10.1038/modpathol.2015.142.

    Article  CAS  PubMed  Google Scholar 

  39. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49(8):1511–23.

    Article  CAS  PubMed  Google Scholar 

  40. Tobon H, Watkins GJ. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol. 1985;4(4):328–35.

    Article  CAS  PubMed  Google Scholar 

  41. Hendrickson MR, Kempson RL. Ciliated carcinoma—a variant of endometrial adenocarcinoma: a report of 10 cases. Int J Gynecol Pathol. 1983;2(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  42. Han G, Lim D, Leitao MM Jr, Abu-Rustum NR, Soslow RA. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology. 2014;64(3):389–98. doi:10.1111/his.12254.

    Article  PubMed  Google Scholar 

  43. Mai KT, Perkins DG, Yazdi HM, Thomas J. Endometrioid carcinoma of the endometrium with an invasive component of minimal deviation carcinoma. Hum Pathol. 2002;33(8):856–8.

    Article  PubMed  Google Scholar 

  44. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol. 2007;26(2):115–23. doi:10.1097/01.pgp.0000233165.56385.0b.

    Article  PubMed  Google Scholar 

  45. Sagae S, Saito T, Satoh M, Ikeda T, Kimura S, Mori M, Sato N, Kudo R. The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading. Oncology. 2004;67(5–6):344–50. doi:10.1159/000082917.

    PubMed  Google Scholar 

  46. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24(9):1201–8.

    Article  CAS  PubMed  Google Scholar 

  47. Guan H, Semaan A, Bandyopadhyay S, Arabi H, Feng J, Fathallah L, Pansare V, Qazi A, Abdul-Karim F, Morris RT, Munkarah AR, Ali-Fehmi R. Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens. Int J Gynecol Cancer. 2011;21(4):654–60. doi:10.1097/IGC.0b013e31821454f1.

    Article  PubMed  Google Scholar 

  48. Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, Miller D, Gilks CB. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 2005;29(3):295–304.

    Article  PubMed  Google Scholar 

  49. Longacre TA, Chung MH, Jensen DN, Hendrickson MR. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol. 1995;19(4):371–406.

    Article  CAS  PubMed  Google Scholar 

  50. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49(12):2547–59.

    Article  CAS  PubMed  Google Scholar 

  51. Heatley MK. Atypical polypoid adenomyoma: a systematic review of the English literature. Histopathology. 2006;48(5):609–10. doi:10.1111/j.1365-2559.2005.02315.x.

    Article  CAS  PubMed  Google Scholar 

  52. Soslow RA, Chung MH, Rouse RV, Hendrickson MR, Longacre TA. Atypical polypoid adenomyofibroma (APA) versus well-differentiated endometrial carcinoma with prominent stromal matrix: an immunohistochemical study. Int J Gynecol Pathol. 1996;15(3):209–16.

    Article  CAS  PubMed  Google Scholar 

  53. Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res. 2010;70(15):6225–32. doi:10.1158/0008-5472.CAN-10-0149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, Herman JG, Esteller M, Matias-Guiu X, Palacios J. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199(4):471–8. doi:10.1002/path.1310.

    Article  CAS  PubMed  Google Scholar 

  55. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28(2):160–7.

    Article  PubMed  Google Scholar 

  56. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29(6):551–8.

    Article  CAS  PubMed  Google Scholar 

  57. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol. 1998;29(9):924–31.

    Article  CAS  PubMed  Google Scholar 

  58. Ross JC, Eifel PJ, Cox RS, Kempson RL, Hendrickson MR. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol. 1983;7(8):715–29.

    Article  CAS  PubMed  Google Scholar 

  59. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002;26(8):998–1006.

    Article  PubMed  Google Scholar 

  60. Chekmareva M, Ellenson LH, Pirog EC. Immunohistochemical differences between mucinous and microglandular adenocarcinomas of the endometrium and benign endocervical epithelium. Int J Gynecol Pathol. 2008;27(4):547–54. doi:10.1097/PGP.0b013e318177eadc.

    Article  PubMed  Google Scholar 

  61. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108.

    Article  CAS  PubMed  Google Scholar 

  62. Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012;22(2):273–9. doi:10.1097/IGC.0b013e318238df4d.

    Article  PubMed  Google Scholar 

  63. Seward S, Ali-Fehmi R, Munkarah AR, Semaan A, Al-Wahab ZR, Elshaikh MA, Cote ML, Morris RT, Bandyopadhyay S. Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system. Int J Gynecol Cancer. 2012;22(3):452–6. doi:10.1097/IGC.0b013e31823de6dd.

    Article  PubMed  Google Scholar 

  64. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26(11):1260–7.

    Article  CAS  PubMed  Google Scholar 

  65. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24(6):797–806.

    Article  CAS  PubMed  Google Scholar 

  66. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.

    Article  CAS  PubMed  Google Scholar 

  67. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117(4):541–5. doi:10.1309/K84K-005F-TCB8-FV4B.

    Article  PubMed  Google Scholar 

  68. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology. 2009;55(4):478–82. doi:10.1111/j.1365-2559.2009.03390.x.

    Article  PubMed  Google Scholar 

  69. Kurman RJ, Scully RE. Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer. 1976;37(2):872–82.

    Article  CAS  PubMed  Google Scholar 

  70. Fadare O, Desouki MM, Gwin K, Hanley KZ, Jarboe EA, Liang SX, Quick CM, Zheng W, Parkash V, Hecht JL. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38(2):189–96. doi:10.1097/PAS.0000000000000085.

    Article  PubMed  Google Scholar 

  71. Fadare O, Parkash V, Gwin K, Hanley KZ, Jarboe EA, Liang SX, Quick CM, Zheng W, Rawish KR, Hecht JL, Desouki MM. Utility of alpha-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas. Hum Pathol. 2013;44(12):2814–21. doi:10.1016/j.humpath.2013.07.033.

    Article  CAS  PubMed  Google Scholar 

  72. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Kobel M, Lee CH. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma–diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology. 2014;64(4):585–96. doi:10.1111/his.12286.

    Article  PubMed  Google Scholar 

  73. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40(3):207–17.

    Article  CAS  PubMed  Google Scholar 

  74. Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol. 1987;156(6):1486–91.

    Article  CAS  PubMed  Google Scholar 

  75. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  76. Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 2010;29(4):343–50. doi:10.1097/PGP.0b013e3181cd6552.

    Article  PubMed  Google Scholar 

  77. Quddus MR, Sung CJ, Zhang C, Lawrence WD. Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci. 2010;17(7):673–8. doi:10.1177/1933719110368433.

    Article  PubMed  Google Scholar 

  78. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228(1):20–30. doi:10.1002/path.4056.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23(6):781–9. doi:10.1038/modpathol.2010.41.

    Article  CAS  PubMed  Google Scholar 

  80. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol. 2006;25(1):52–8.

    Article  PubMed  Google Scholar 

  81. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316–21.

    Article  PubMed  Google Scholar 

  82. Seidman JD, Chauhan S. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol. 2003;22(1):75–82.

    Article  PubMed  Google Scholar 

  83. Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol. 1997;67(3):316–21. doi:10.1006/gyno.1997.4875.

    Article  CAS  PubMed  Google Scholar 

  84. de Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol. 1993;24(2):132–42.

    Article  PubMed  Google Scholar 

  85. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9(1):1–19.

    Article  CAS  PubMed  Google Scholar 

  86. Gonzalez-Bosquet E, Gonzalez-Bosquet J, Garcia Jimenez A, Gil A, Xercavins J. Carcinoid tumor of the uterine corpus. A case report. J Reprod Med. 1998;43(9):844–6.

    CAS  PubMed  Google Scholar 

  87. Chetty R, Clark SP, Bhathal PS. Carcinoid tumour of the uterine corpus. Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93–5.

    Article  CAS  PubMed  Google Scholar 

  88. Starzynski S, Kubicka-Pertkiewicz M. Carcinoid of the uterine corpus. Patol Pol. 1978;29(2):237–40.

    CAS  PubMed  Google Scholar 

  89. Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol. 1994;18(4):364–75.

    Article  CAS  PubMed  Google Scholar 

  90. van Hoeven KH, Hudock JA, Woodruff JM, Suhrland MJ. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol. 1995;14(1):21–9.

    Article  PubMed  Google Scholar 

  91. Deodhar KK, Kerkar RA, Suryawanshi P, Menon H, Menon S. Large cell neuroendocrine carcinoma of the endometrium: an extremely uncommon diagnosis, but worth the efforts. J Cancer Res Ther. 2011;7(2):211–3. doi:10.4103/0973-1482.82942.

    Article  PubMed  Google Scholar 

  92. Zaino RJ. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol. 2009;28(1):1–9. doi:10.1097/PGP.0b013e3181846c6d.

    Article  PubMed  Google Scholar 

  93. Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011;21(3):511–6. doi:10.1097/IGC.0b013e31820cc305.

    Article  PubMed  Google Scholar 

  94. Haltia UM, Butzow R, Leminen A, Loukovaara M. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol. 2014;25(1):30–5. doi:10.3802/jgo.2014.25.1.30.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Kim HS, Kim HY, Park CY, Lee JM, Lee JK, Cho CH, Kim SM, Kim JW. Lymphadenectomy increases the prognostic value of the revised 2009 FIGO staging system for endometrial cancer: a multi-center study. Eur J Surg Oncol. 2012;38(3):230–7. doi:10.1016/j.ejso.2011.12.023.

    Article  CAS  PubMed  Google Scholar 

  96. Werner HM, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Amant F, Salvesen HB, MoMa TECsg. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol. 2012;125(1):103–8. doi:10.1016/j.ygyno.2011.11.008.

    Article  CAS  PubMed  Google Scholar 

  97. Korczynski J, Jesionek-Kupnicka D, Gottwald L, Piekarski J. Comparison of FIGO 1989 and 2009 recommendations on staging of endometrial carcinoma: pathologic analysis and cervical status in 123 consecutive cases. Int J Gynecol Pathol. 2011;30(4):328–34. doi:10.1097/PGP.0b013e3182069c30.

    Article  PubMed  Google Scholar 

  98. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40(1):55–65.

    Article  CAS  PubMed  Google Scholar 

  99. Bosse T, Peters EE, Creutzberg CL, Jurgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742–50. doi:10.1016/j.ejca.2015.05.015.

    Article  PubMed  Google Scholar 

  100. Hachisuga T, Kaku T, Fukuda K, Eguchi F, Emoto M, Kamura T, Iwasaka T, Kawarabayashi T, Sugimori H, Mori M. The grading of lymphovascular space invasion in endometrial carcinoma. Cancer. 1999;86(10):2090–7.

    Article  CAS  PubMed  Google Scholar 

  101. Han KH, Park NH, Kim HS, Chung HH, Kim JW, Song YS. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. Gynecol Oncol. 2014;134(2):293–6. doi:10.1016/j.ygyno.2014.05.010.

    Article  PubMed  Google Scholar 

  102. Group AES, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46. doi:10.1016/S0140-6736(08)61767-5.

    Article  Google Scholar 

  103. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, Lybeert ML, Slot A, Lutgens LC, Stenfert Kroese MC, Beerman H, van Lent M. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. J Clin Oncol. 2004;22(7):1234–41. doi:10.1200/JCO.2004.08.159.

    Article  PubMed  Google Scholar 

  104. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. doi:10.1158/1078-0432.CCR-11-2283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C, French Cancer Genetics N. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10. doi:10.1001/jama.2011.743.

    Article  CAS  PubMed  Google Scholar 

  106. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66(15):7810–7. doi:10.1158/0008-5472.CAN-06-1114.

    Article  CAS  PubMed  Google Scholar 

  107. Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38(11):1501–9. doi:10.1097/PAS.0000000000000321.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Hospital Graz Sued-West, Academic Teaching Hospital of the Medical University, LKH Graz Süd-West, Standort West, Göstingerstrasse 22, 8020, Graz, Austria

    Sigurd F. Lax

Authors
  1. Sigurd F. Lax
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sigurd F. Lax .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA

    Michael T. Deavers

  2. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA

    Donna M. Coffey

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lax, S.F. (2017). Classification of Endometrial Carcinoma. In: Deavers, M., Coffey, D. (eds) Precision Molecular Pathology of Uterine Cancer. Molecular Pathology Library, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-319-57985-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-57985-6_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-57983-2

  • Online ISBN: 978-3-319-57985-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation